Heptaplatin
Heptaplatin is a platinum-complexed anticancer chemotherapeutic compound approved in some countries for the treatment of gastric cancers. Heptaplatin exhibits anti-proliferative activity in models of head and neck squamous cell cancers when combined with 5-fluorouracil (5-FU) as well as other, separate cancer cell lines.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18930721
| Cas No. |
146665-77-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C11H20N2O6Pt |
| Formula Wt. |
471.36 |
| Chemical Name |
[SP-4-2-[4R-(2a,4a,5b)]]-[2-(1-Methylethyl)-1,3-dioxolane-4,5-dimethanamine-N,N][propanedioato(2-)-O,O]-platinum |
| IUPAC Name |
[(4R,5R)-5-(aminomethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methanamine;platinum;propanedioic acid |
| Synonym |
Eptaplatin |
| Appearance |
White to off white powder |
Lee JW, Park JK, Lee SH, et al. Anti-tumor activity of heptaplatin in combination with 5-fluorouracil or paclitaxel against human head and neck cancer cells in vitro. Anticancer Drugs. 2006 Apr;17(4):377-84. PMID: 16549994.
Kim NK, Im SA, Kim DW, et al. Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma. Cancer. 1999 Oct 1;86(7):1109-15. PMID: 10506693.
Kim DK, Kim HT, Tai JH, et al. Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol. 1995;37(1-2):1-6. PMID: 7497577.
